Results 81 to 90 of about 90,057,531 (289)
Access to research and access to medicines
, 2007 Gavin Yamey, Access to university research and innovations, <em> PLoS Blog </em> , August 6, 2007. (Thanks to Gavin Baker.) Excerpt: <b> Update </b> . See the good comments of Steven Salzberg.
openaire +1 more source
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Introduction This study investigated the safety and efficacy of single‐needle Rheocarna therapy for chronic limb‐threatening ischemia (CLTI) with wounds. Methods Six patients with CLTI involving ulcers unresponsive to revascularization underwent single‐needle Rheocarna treatment.
Yasutaka Yamauchi +9 more
wiley +1 more source
Revista de Saúde Pública, 2017 OBJETIVE: To analyze the relationship between access to medicines by the population and the institutionalization of pharmaceutical services in Brazilian primary health care. METHODS: This study is part of the Pesquisa Nacional sobre Acesso, Utilização e Promoção do Uso Racional de Medicamentos – Serviços 2015 (PNAUM – National Survey on Access, Use and
Barros, Rafael Damasceno +11 more
openaire +6 more sources
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Background Patients with chronic kidney disease undergoing hemodialysis commonly experience reduced physical function, fatigue, poor sleep quality, and impaired health‐related quality of life. Intradialytic exercise has been proposed as a non‐pharmacological strategy to improve these outcomes.
Klebson da Silva Almeida +6 more
wiley +1 more source
Investing For Life: Meeting poor people's needs for access to medicines through responsible business practices [PDF]
, 2007 There are major shortcomings in the pharmaceutical industry's current initiatives to ensure that poor people have access to medicines. To shore up its own flagging economic performance, the industry is increasingly looking to the potentially huge markets
Dhanarajan, Sumi +2 more
core +1 more source
BMC International Health and Human Rights, 2018 Background WHO has a pivotal role to play as the leading international agency promoting good practices in health and human rights. In 2005, mifepristone and misoprostol were added to WHO’s Model List of Essential Medicines for combined use to terminate ...
Katrina Perehudoff +2 more
doaj +1 more source
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Background Establishing a comprehensive apheresis medicine program in a resource‐constrained setting presents significant structural, financial, and logistical challenges. Despite the growing clinical importance of apheresis services globally, published experience from sub‐Saharan Africa remains sparse.
Folasade Adelekan‐Popoola +4 more
wiley +1 more source
Pricing of drugs and donations: options for sustainable equity pricing. [PDF]
, 2001 Effective medicines exist to treat or alleviate many diseases which predominate in the developing world and cause high mortality and morbidity rates. Price should not be an obstacle preventing access to these medicines.
Herranz, E, Pérez-Casas, C, Ford, N
core
The business case for vaccine and drug manufacturing in middle-income countries
The Lancet Global Health, 2022 Lenias Hwenda
doaj +1 more source
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Background Maintenance hemodialysis (MHD) patients frequently suffer from frailty, characterized by reduced physical function and poor prognosis. Myokines, such as myonectin, secreted by muscle, are emerging regulators of systemic health. This study investigated the relationship between serum myonectin, adipokines (adiponectin, omentin), and ...
Kenichi Kono +7 more
wiley +1 more source